ATC Group: N02BG08 Ziconotide

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N02BG08 in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N02 Analgesics
3 N02B Other analgesics and antipyretics
4 N02BG Other analgesics and antipyretics
5 N02BG08 Ziconotide

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
PAREN - Parenteral 12 ug

Active ingredients in N02BG08

Active Ingredient Description
Ziconotide

Ziconotide is a synthetic analogue of a ω-conopeptide, MVIIA, found in the venom of the Conus magus marine snail. It is an N-type calcium channel blocker (NCCB). In binding to these neuronal NCCs ziconotide inhibits the voltage sensitive calcium current into primary nociceptive afferents terminating in the superficial layers of the dorsal horn of the spinal cord.

Related product monographs

Title Information Source Document Type  
PRIALT Solution for infusion European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Austria (AT)

Cyprus (CY)

Estonia (EE)

Finland (FI)

France (FR)

Ireland (IE)

Lithuania (LT)

Netherlands (NL)

Poland (PL)

Romania (RO)

Spain (ES)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.